Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Tactics used x Hedge Fund & MM to acquire shareholder stock

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 20, 2022 5:48pm

228 Views

Post# 35114196

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

Don't get your shorts in knot over Adlai Nortye since ONCY is responsible for all of the manufacturing of pelareorep and as such retains full control over the intellectual property and manufacturing processes for the virus. If Adlai Nortye gains approved for pelareorep China Adlai Nortye would have exclusive marketing rights but ONCY would be supplying the drug.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec